$ALHC

Kaplan Fox said it is investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) after a former executive filed a whistleblower complaint alleging accounting irregularities that allegedly inflated reported and projected results, including Adjusted EBITDA. The complaint also alleges operating expenses were misclassified as capital expenditures. On July 8, 2026, ALHC shares fell $4.02, or 16.7%, to close at $20.03.

Kaplan Fox & Kilsheimer LLP said it is investigating potential securities violations at Alignment Healthcare, Inc. (NASDAQ: ALHC) after a whistleblower complaint alleging accounting irregularities that allegedly inflated previously reported and projected results. The complaint cites operating expenses allegedly misclassified as capital expenditures, affecting Adjusted EBITDA. On July 8, 2026, ALHC shares fell $4.02, or 16.7%, to close at $20.03.

Alignment Healthcare, a Medicare Advantage insurer, secured a $200 million credit line from Citibank on Feb. 26, 2026, running three years for permitted acquisitions. As of June 30, 2026, it had not drawn on the facility. In a July 30, 2026 SEC filing, it said it expects to acquire provider groups and Medicare Advantage plans. Alignment operates in 45 markets with 294,100 members.

KAO JOHN E (Chief Executive Officer) sold 298,000 indirectly-held shares of Alignment Healthcare, Inc. (ALHC) at $13.88 ($4.14M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Alignment Healthcare (ALHC) says its Medicare Advantage economics are improving via AI automation. In Q1 2026, auto-adjudication rose above 60% from under 15% a year earlier, with adjusted SG&A down 60 bps and adjusted EBITDA margin up 90 bps. ALHC targets 2026 revenue of $5.19B (+31.4% YoY) and highlights 4+ star ratings and retention, while CMS V28 risk adjustment adds uncertainty.

Alignment Healthcare (ALHC) reported Q2 2026 revenue of $1.34B and net income of $36.56M, with diluted EPS of $0.17. For the first half, net income rose to $47.98M. The company raised full-year 2026 revenue guidance to $5.20B to $5.23B, citing continued momentum, while noting Medicare Advantage regulatory and reimbursement risks.

Kaplan Fox & Kilsheimer LLP said it is investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) after a July 8, 2026 whistleblower complaint alleged accounting irregularities that allegedly inflated reported and projected results, including Adjusted EBITDA, and misclassified operating expenses as capital expenditures. After the news, ALHC shares fell $4.02, or 16.7%, to close at $20.03.

Alignment Healthcare (ALHC) reported Q2 EPS of 17 cents, up from 7 cents a year earlier, with revenue rising 31.6% to $1.34B and beating consensus. Membership reached about 294,100. The company raised 2026 guidance to $5.195B-$5.225B revenue and 298,000-301,000 membership, but expects lower Q3 adjusted EBITDA ($20M-$30M) due to added clinical, AI and expansion spending.

Alignment Healthcare (ALHC) reported Q2 2026 membership up 31.5% to about 294,100 and revenue up 31.6% to $1.34 billion. Adjusted gross profit rose 35.3% to $182.9 million and adjusted EBITDA rose 48.4% to $68.1 million. Management raised full-year 2026 outlook to 298,000-301,000 members and $5.20-$5.23 billion revenue, while valuation remains mixed versus peers.

Kaplan Fox said a former Alignment Healthcare executive filed a whistleblower complaint alleging accounting irregularities that allegedly inflated reported and projected results, including Adjusted EBITDA, and misclassified operating expenses as capital expenditures. After the July 8, 2026 report, ALHC shares fell $4.02, or 16.7%, to close at $20.03, according to the article.